Numeric Investors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Numeric Investors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-13,800	Closed	-$142K	–	981
2015 Q4	$142K	Buy	+13,800	New	+$137K	﹤0.01%	940
2014 Q4	–	Sell	-10,800	Closed	-$106K	–	839
2014 Q3	$106K	Buy	+10,800	New	+$132K	﹤0.01%	782

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Numeric Investors's BCRX Position: Q1 2016 in Review

Numeric Investors sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2016, closing a stake of 13,800 shares — an estimated $142K sold.

Numeric Investors first reported a position in BCRX in Q3 2014 and held it in 2 quarters. The position peaked at $142K in Q4 2015. 109 funds tracked by Wall St. Rank hold BCRX as of Q1 2016.

Numeric Investors reported no remaining BioCryst Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Numeric Investors sold 13,800 BioCryst Pharmaceuticals shares in Q1 2016, an estimated $142K.
Numeric Investors first reported a position in BioCryst Pharmaceuticals in Q3 2014 and held it in 2 quarters.
Numeric Investors's BioCryst Pharmaceuticals position peaked at $142K in Q4 2015.
109 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2016.

Based on Numeric Investors's 13F filing for Q1 2016, filed 6 May 2016.